Meeting Announcement: Aprea Therapeutics to Present at the 7th International Mutant p53 Workshop in Melbourne, Australia

October 22, 2016—Dr. Mikael von Euler will present data from Aprea Therapeutics’ Phase Ib study in high-grade serous ovarian cancer at the 7th International Mutant p53 Workshop in Melbourne, Australia. This oral presentation is scheduled for 11:35 AM on Friday October 28, 2016 as part of Session 11: Mutant p53 therapies.

Presentation title: PISARRO: A EUTROC phase 1b study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC)